Sign in

    Sarah Medeiros

    Biopharma & Biotech Equity Research Associate at Cantor Fitzgerald

    Sarah Medeiros is a Biopharma & Biotech Equity Research Associate at Cantor Fitzgerald, specializing in financial analysis and healthcare sector research focused on biotechnology and pharmaceutical companies. She has covered companies including Arcturus Therapeutics Holdings Inc. and Acumen Pharmaceuticals, participating in earnings calls and providing analytical support on key industry developments. Since joining Cantor Fitzgerald, she has contributed to equity research within the biopharma space, leveraging her expertise in financial modeling and healthcare trends, though independently verifiable rankings or success rate metrics are not available. Medeiros holds advanced industry knowledge and operates as part of Cantor Fitzgerald’s biotechnology research team, evidencing strong analytical capabilities in public company evaluation.

    Sarah Medeiros's questions to Arcturus Therapeutics Holdings (ARCT) leadership

    Sarah Medeiros's questions to Arcturus Therapeutics Holdings (ARCT) leadership • Q2 2025

    Question

    Sarah Medeiros of Cantor Fitzgerald asked how FEV1 data would be presented, considering patient baselines, and what other measurements, such as quality of life, would be used to support the CF program's efficacy.

    Answer

    President and CEO Joseph Payne explained they will analyze FEV1 using an "area under the curve" approach and noted that most participants have a baseline FEV1 in the 60-80% range. He also confirmed the use of the standardized CF Questionnaire-Revised (CFQ-R) to measure quality of life, providing an additional supportive endpoint.

    Ask Fintool Equity Research AI